NEW YORK, March 29, 2018 (GLOBE NEWSWIRE) -- According to a new research report titled “Bronchiectasis Therapeutics Pipeline Analysis 2017” published by P&S Market Research, Bronchiectasis currently exhibits a pipeline with 13 drug candidates.
Request for Sample Copy of this Research Report: https://www.psmarketresearch.com/market-analysis/bronchiectasis-therapeutics-pipeline-analysis/report-sample
The study analysed that the Bronchiectasis therapeutics pipeline comprises approximately 13 drug candidates in different stages of development. Bronchiectasis is a condition in which damage to the airways causes them to widen and become flabby and scarred. The airways are tubes that carry air in and out of lungs. Bronchiectasis usually is the result of an infection or other condition that injures the walls of airways or prevents the airways from clearing mucus. In bronchiectasis, the airways slowly lose their ability to clear out mucus. When mucus cannot be cleared, it builds up and creates an environment in which bacteria can grow. This leads to frequent and serious lung infections.
Insmed’s liposomal technology is designed specifically for the delivery of pharmaceuticals to the lung. Liposomes are the microscopic membrane shells that contain water. In a liposome drug delivery system, water-soluble drugs such as amikacin, are located in the liposome’s water core. The liposome delivery system delivers medicine directly to the site of the lung infection. The infecting bacteria invade and multiply mainly within macrophages. The materials found in a patient’s mucus and biofilms that are produced by bacteria to protect themselves have negative charges which attracts opposite charged antibiotics such as amikacin.
Browse Full Report with detailed TOC on “Bronchiectasis Therapeutics Pipeline Analysis” at: https://www.psmarketresearch.com/market-analysis/bronchiectasis-therapeutics-pipeline-analysis
The research also found that there are several companies that use synthetic sources for the development of drugs for the treatment of bronchiectasis.
Some of the other key players developing drugs for the treatment of bronchiectasis include Aradigm Corporation, Bayer AG, Zambon SpA and others.
More Reports Published by P&S Market Research
Sjögren’s Syndrome Therapeutics Pipeline Analysis - https://www.psmarketresearch.com/market-analysis/sjogrens-syndrome-therapeutics-pipeline-analysis
IgA Nephropathy Pipeline Analysis - https://www.psmarketresearch.com/market-analysis/iga-nephropathy-pipeline-analysis
About P&S Market Research
P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.
As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.
Contact:
P&S Market Research
347, 5th Ave. #1402
New York City, NY - 10016
Toll-free: +1-888-778-7886 (USA/Canada)
Email: enquiry@psmarketresearch.com